期刊文献+

硫化砷诱导HL-60细胞凋亡中端粒酶活性和hTERT mRNA表达的改变 被引量:5

Changes of telomerase activity and hTERT mRNA expression in the process of apoptosis of HL-60 cells in- duced by arsenic sulfide
下载PDF
导出
摘要 目的:探讨硫化砷在诱导急性非淋巴细胞白血病(APL)细胞株HL-60凋亡的同时,对端粒酶活性的影响及作用机制。方法:采用PCR-ELISA法测定端粒酶活性;半定量RT-PCR检测hTERT mRNA的表达;流式细胞仪分析细胞周期、细胞 凋亡及CD11b表达。结果:用0.3-0.6 mg/L的硫化砷作用72 h,不能诱导HL-60细胞凋亡,将剂量增至1.5-3.0 mg/L时,凋亡细胞的比率逐渐增高,同时伴随HL-60细胞端粒酶活性和hTERT mRNA表达受抑。随着硫化砷浓度的增高,HL-60细胞在G2/M期的比率渐增高。3.0 mg/L的硫化砷作用72 h,HL-60细胞CD11b的表达由1.27%升至6.07%。结论:硫化砷在诱导HL-60细胞凋亡的同时,下调其端粒酶活性。G2/M期细胞比率的增高可能与端粒酶活性降低相关。高浓度硫化砷72 h可轻度诱导HL-60细胞分化。 AIM: To explore the effect of arsenic sulfide on telomerase activity of HL-60 cells. METHODS: Telomerase activity was determined by PCR-ELISA. The expression of hTERT-mR-NA was analyzed by semi-quantitative RT-PCR. Flow cy-tometry was used to analyze the cell cycle, apoptosis and CDllb expression of HL-60 cells. RESULTS: Treament of HL-60 cells with 0.3 -0.6 mg/L arsenic sulfide for 72 h did not induce apoptosis of the cells, while 1.5-3.0 mg/L did. Furthermore, 1.5 -3.0 mg/L arsenic sulfide inhibited the telomerase activity and hTERT-mRNA expression in HL-60 cells. Proportion of the cells in Q2/M phase was increased when being treated with arsenic sulfide. 3. 0 mg/L arsenic sulfide upregulated CDllb expression in HL-60 cells from 1.0% to 6. 8%. CONCLUSION: Arsenic sulfide can inhibit telomerase activity. The increase of proportion of HL-60 cells in G2/M phase may be related to the reduction of telomerase activity. High dosage of arsenic sulfide can slightly induce differentiation of HL-60 cells.
作者 李静 刘陕西
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2003年第6期595-597,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 西安市科委科技攻关基金资助(No.200016)
关键词 硫化砷 端粒酶 细胞周期 细胞凋亡 HL-60细胞 arsenic sulfide telomerase cell cycle apopto- sis HL-60 cell
  • 相关文献

参考文献1

二级参考文献13

  • 1[1]Chao N, Hua Y, Ting Y et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, fellow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients [J]. Blood, 1999; 94(10):3315.
  • 2[2]Dao PL, Jing YQ, Bin J et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: A pilot report [J]. Blood, 2002;99(9):3136.
  • 3[5]Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer [J]. Science, 1994; 266:2011.
  • 4[6]Meyeson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunit gene is up-regulated in tumor cells and during immortalization [J]. Cell, 1997; 90:785.
  • 5[7]Fu W, Begley JG, Killen MW et al. Antiapoptotic role of telomerase in pheochromocytoma cells [J]. J Biol Chem, 1999; 274:7264.
  • 6[8]Mandal M, Kumar R. Bcl-2 modulates telomerase activity [J]. J Biol Chem, 1997; 272:14183.
  • 7[9]Chen GQ, Zhu J, Shi XG et al. In vitro studies on cellular and molecular mechanism of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down-regulation of bcl-2 expression and modulation of PML-RARα/PML proteins [J]. Blood, 1996; 88:1052.
  • 8[10]Tom KH, Su XL, Charles W. Mutagenicity of arsenic in mammalian cell: Role of reactive oxygen species [J]. Proc Natl Acad Sci USA, 1998; 95:8103.
  • 9[11]Satoru K, Masahiro T, Takahiro T et al. SPI cooperate with c-myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT) [J]. Nucleic Acids Res, 2000; 28: 669.
  • 10[12]Rosatio A, Maria M, Tommaso R et al. The DNA-binding efficiency of SP1 is affected by redox changes [J]. Eur J Biochem, 1994; 225:483.

同被引文献102

引证文献5

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部